This small business innovation research phase i proposal will focus on developing a deoxyribonucleic acid based binder of neurotoxins that also catalyzes deactivation of the agent, rendering IT…
Ended Purchase Order Awarded Last action
- Contract number
- W911NF25PA013
- Awardee
-
Nanohmics Inc. UEI K39ENMXNLA73
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $209,573
Award facts
- Contract value 100% obligated
- $209,573.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Research Development and Engineering Command Army Materiel Command, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78741, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $209,573 |
About this award
The U.S. Army Research, Development and Engineering Command has awarded a Phase I Small Business Innovation Research (SBIR) contract to Nanohmics Inc., an Austin, Texas-based technology development firm specializing in advanced electronics, optics, and sensor systems. Under this $209,573.26 firm fixed-price purchase order, Nanohmics will develop a deoxyribonucleic acid (DNA)-based binder designed to neutralize neurotoxins while simultaneously catalyzing their deactivation, rendering them ineffective as chemical warfare agents. This research initiative is set aside exclusively for small businesses and represents the type of dual-function biotechnology innovation characteristic of SBIR Phase I efforts, which typically fund feasibility studies and proof-of-concept research. The contract is scheduled for completion by February 28, 2026, with an award date of August 1, 2025.
Nanohmics brings substantial relevant experience to this engagement, having secured numerous federal contracts with defense agencies including the Air Force Research Laboratory, Naval Air Warfare Center, and Missile Defense Agency across multiple SBIR phases. The company maintains a Basic Ordering Agreement with the Naval Air Warfare Center for SBIR Phase II activities, demonstrating its established capability in advanced defense research and development. The DNA-based neurotoxin binder project aligns with the Department of Defense's chemical and biological defense priorities and reflects the SBIR program's emphasis on innovative technological solutions addressing critical national security challenges.
Description
This small business innovation research phase i proposal will focus on developing a deoxyribonucleic acid based binder of neurotoxins that also catalyzes deactivation of the agent, rendering IT ineffective as a warfare weapon.
Quick answers
Who was awarded contract W911NF25PA013?
W911NF25PA013 was awarded to Nanohmics Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on August 1, 2025.
How much is contract W911NF25PA013 worth?
The government has obligated $209,573 on W911NF25PA013.
Which agency awarded contract W911NF25PA013?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911NF25PA013, with funding from Research Development and Engineering Command (Army Materiel Command).
Was contract W911NF25PA013 competed?
The extent of competition for W911NF25PA013 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award